Guardant Health Inc. Stock News

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list,

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studi

From a technical perspective, Guardant Health (GH) is looking like an interesting pick, as it just reached a key level of support. GH recently overtook the 200-day moving average, and this suggests a

Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Admini

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Mol

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Willia

DALLAS--(BUSINESS WIRE)--Trinity Industries, Inc. (“Trinity” or the “Company”) today announced that it intends to offer (the “Offering”) an additional $200.0 million aggregate principal am

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Unio

Amalgamated Bank cut its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securi

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Dis

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall S

Guardant Health (GH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.30 per share a year ago.